Literature DB >> 23582919

Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

George Kanakis1, Gregory Kaltsas.   

Abstract

Biochemical markers are applied in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) for diagnostic, prognostic or predictive purposes. Chromogranin A is the most important general marker and it is recommended to be measured in every patient with a suspected NET, whereas Neuron Specific Enolase is elevated mainly in poorly differentiated NETs. Pancreatic Polypeptide is used in the diagnosis of pancreatic non-functioning NETs, whereas Chorionic Gonadotrophin has an adjunctive role. In the case of functioning tumours, specific markers should be sought and monitored during follow up. Endogenous hyperinsulinemia is suggested in the presence of non-suppressible insulin and proinsulin levels during hypoglycemia, whereas high fasting or stimulated gastrin levels along with elevated gastric acid output are diagnostic for the Zollinger-Ellison syndrome. Glucagon, vasoactive intestinal polypeptide (VIP) and somatostatin are markers for glucagonoma, VIP-oma and somatostatinoma syndromes respectively. In case of ectopic paraneoplastic syndrome, the relevant hormone serves as a diagnostic and prognostic marker.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23582919     DOI: 10.1016/j.bpg.2012.12.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  32 in total

Review 1.  The functioning side of the pancreas: a review on insulinomas.

Authors:  I Maggio; V Mollica; N Brighi; G Lamberti; L Manuzzi; A D Ricci; D Campana
Journal:  J Endocrinol Invest       Date:  2019-07-31       Impact factor: 4.256

2.  The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.

Authors:  I M Modlin; M Kidd; L Bodei; I Drozdov; H Aslanian
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 3.  Carcinoid Heart Disease: Review of Current Knowledge.

Authors:  Pradhum Ram; Jorge L Penalver; Kevin Bryan U Lo; Janani Rangaswami; Gregg S Pressman
Journal:  Tex Heart Inst J       Date:  2019-02-01

4.  Pancreatic Neuroendocrine Tumors: an Update.

Authors:  Alessandro Paniccia; Barish H Edil; Richard D Schulick
Journal:  Indian J Surg       Date:  2015-10-13       Impact factor: 0.656

5.  Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.

Authors:  L Bodei; M Kidd; I M Modlin; V Prasad; S Severi; V Ambrosini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli; I Drozdov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-07       Impact factor: 9.236

6.  Decline of serum CA724 as a probable predictive factor for tumor response during chemotherapy of advanced gastric carcinoma.

Authors:  Li Zou; Jun Qian
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

7.  Rare diseases in clinical endocrinology: a taxonomic classification system.

Authors:  G Marcucci; L Cianferotti; P Beck-Peccoz; M Capezzone; F Cetani; A Colao; M V Davì; E degli Uberti; S Del Prato; R Elisei; A Faggiano; D Ferone; C Foresta; L Fugazzola; E Ghigo; G Giacchetti; F Giorgino; A Lenzi; P Malandrino; M Mannelli; C Marcocci; L Masi; F Pacini; G Opocher; A Radicioni; M Tonacchera; R Vigneri; M C Zatelli; M L Brandi
Journal:  J Endocrinol Invest       Date:  2014-11-07       Impact factor: 4.256

8.  Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Authors:  Marianne E Pavel; Alexandria T Phan; Edward M Wolin; Beloo Mirakhur; Nilani Liyanage; Susan Pitman Lowenthal; George A Fisher; Aaron I Vinik
Journal:  Oncologist       Date:  2018-10-24

9.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 10.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.